Coherus BioSciences, Inc.

As of September 3, 2025, Coherus BioSciences, Inc. shows a mildly bullish trend with strong short-term performance, having outperformed the S&P 500 recently, but it has underperformed over the longer term.

Coherus BioSciences, Inc. has a risky valuation grade due to negative metrics like a Price to Book Value of -0.52 and a concerning ROCE of -350.73%, indicating overvaluation despite a recent stock surge, with long-term performance significantly lagging behind the S&P 500.

As of May 6, 2021, Coherus BioSciences, Inc. is considered overvalued and risky due to negative financial metrics, including a P/B ratio of -0.52, an EV/EBITDA ratio of -3.01, a ROCE of -350.73%, and a year-to-date return of -47.34%, significantly underperforming the S&P 500.

As of June 3, 2025, the trend is mildly bearish due to bearish weekly MACD and moving averages, despite some underlying strength indicated by the KST and a mildly bullish monthly MACD, while the stock has underperformed the S&P 500.

As of March 2022, the management team of Coherus BioSciences, Inc. includes Dennis Lanfear (Chairman, President, CEO), Mats Wahlstrom (Lead Independent Director), Alan Mendelson, Mark Stolper, Kimberly Tzoumakas (Directors), and James Healy (Independent Director). They are responsible for the company's strategic direction and operations.

Coherus BioSciences, Inc. is a late-stage clinical biologics company focused on developing and commercializing biosimilar products. As of March 2025, it reported net sales of $8 million and a net loss of $47 million, with a market cap of $87.88 million.

As of Jun 18, Coherus BioSciences, Inc. has a market capitalization of 87.88 million and reported net sales of 197.49 million with a net profit of -121.77 million over the latest four quarters. As of Dec 24, shareholder's funds were -131.99 million and total assets were 454.85 million.